DPP4-inhibitors in T2DM: What does the EVIDENCE really say?

Prof. Stephan Jacob emphasizes the importance of evidence in understanding the effectiveness and safety of DPP4 inhibitors, particularly Linagliptin. He highlights the results from two cardiovascular outcome trials, CAROLINA and CARMELINA, which demonstrated Linagliptin’s CV and renal safety across a broad range of patients. Prof. Jacob also discusses the importance of appropriate dosing for DPP4 inhibitors, noting that Linagliptin's unique 5 mg once-daily dose is convenient and avoids the need for dose titration based on renal function. He concludes by questioning the validity of claims made by other DPP4 inhibitors without proper evidence from large-scale trials and emphasizes the importance of using medications with proven safety and efficacy to avoid potential risks such as heart failure and hypoglycemia.

Estimated time of Completion: 35 mins